Loading...
Market
Will Moderna's stock price increase by 10% or more by Dec 31, 2024, after Health Canada approval?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial platforms such as Yahoo Finance or Bloomberg
Story
Moderna's mRESVIA RSV Vaccine Approved by Health Canada for Adults 60 and Older
Nov 8, 2024, 03:13 PM
Moderna has received approval from Health Canada for its respiratory syncytial virus (RSV) vaccine, mRESVIA, for adults aged 60 years and older. This marks the first mRNA-based vaccine for RSV to be authorized in Canada. The approval was announced on Friday, making it a significant milestone for the vaccine maker. The stock ticker for Moderna is $MRNA.
View original story
Similar markets
Outperforms S&P 500 • 25%
Matches S&P 500 • 25%
Underperforms S&P 500 • 25%
Declines • 25%
Decrease by more than 10% • 25%
Change between -10% and 10% • 25%
Increase by 10% to 20% • 25%
Increase by more than 20% • 25%
Yes • 50%
No • 50%
